POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.259
https://www.valueinhealthjournal.com/article/S1098-3015(21)02054-4/fulltext
Title :
POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02054-4&doi=10.1016/j.jval.2021.11.259
First page :
Section Title :
Open access? :
No
Section Order :
11030